Cosentyx® (secukinumab) in the real world
Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active moderate to severe hidradenitis suppurativa (HS; acne inversa) in adults with an inadequate response to conventional systemic HS therapy; active enthesitis-related arthritis (ERA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active juvenile psoriatic arthritis (JPsA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.1
Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated.1
In Ireland Cosentyx is reimbursed for the following indications: adult plaque psoriasis (PsO); psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).
Please refer to the Summary of Product Characteristics (SmPC) for full prescribing information and safety profile.1
SERENA: Long-term real-world evidence on retention with Cosentyx in PsA and AS2,3
Explore our video series showcasing the latest outputs from SERENA, the largest prospective, longitudinal, non-interventional study in adult patients with active PsA or active AS after 5 years. These results have recently been presented at ACR 2025 and EULAR 2025 congresses.2,4–8
Meet the Principal Investigator
Dr Nicola Gullick is a Consultant in Rheumatology at the University Hospitals Coventry and Warwickshire (UHCW), UK, and the Principal Investigator for the SERENA study in the UK.
With over 13 years of expertise as a Consultant Rheumatologist, Dr Gullick is an honorary Lecturer at the University of Warwick, Chair of the British Psoriatic Arthritis Consortium, and an active member of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).
Dr Gullick has authored over 50 scientific publications and contributes to treatment guideline development for the British Society for Rheumatology and GRAPPA.
SERENA: Study overview
>2,900 patients treated with Cosentyx2
438 sites2 (19 countries)
Duration up to 5 years2
Primary objective: Assess the long-term retention, effectiveness, and safety of Cosentyx in routine clinical practice for the treatment of moderate to severe PsO, active PsA and AS.2,3
Dr Nicola Gullick and Dr Catherine Hughes (Consultant Rheumatologist, Tallaght University Hospital) discuss the objectives and study design of the SERENA study and the relevance of real-world data.
Dr Nicola Gullick and Dr Catherine Hughes discuss real-world retention rates with Cosentyx after 5 years in the SERENA study.
Dr Nicola Gullick and Dr Catherine Hughes present the 5-year sustained efficacy outcomes with Cosentyx from the SERENA study, and discuss the role retention rates play when selecting a biological therapy.
Dr Nicola Gullick and Dr Catherine Hughes discuss the long-term safety profile with Cosentyx and reasons for discontinuation in the SERENA study.
Dr Nicola Gullick and Dr Catherine Hughes discuss first-line biologic choice, and the value of switching mode of action.
Dr Nicola Gullick and Dr Catherine Hughes discuss the difference in retention rates between biologic-naïve and biologic-exposed patients in the SERENA study, and potential factors behind them.
Dr Nicola Gullick and Dr Catherine Hughes discuss the value of real-world evidence.
Dr Nicola Gullick and Dr Catherine Hughes summarise the impact of the SERENA study on their clinical practice.
Beaumont Hospital talk: Long-term outcomes from SERENA
Watch Dr Nicola Gullick presenting the most recent outcomes from the real-world SERENA study on retention rates and sustained efficacy with Cosentyx after 5 years in eligible PsA and AS patients.
Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated. Please refer to the Cosentyx SmPC for full product information before prescribing.1
AS, ankylosing spondylitis; axSpA, axial spondyloarthritis; ERA; enthesitis-related arthritis; GRAPPA, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis; HS, hidradenitis suppurativa; JPsA, juvenile psoriatic arthritis; MTX, methotrexate; PsA, psoriatic arthritis; PsO, plaque psoriasis; SmPC, summary of product characteristics; UHCW, University Hospitals Coventry and Warwickshire.
References
- Cosentyx® (secukinumab) Summary of Product Characteristics. Available at: www.medicines.ie.
- Kiltz U, et al. Adv Ther 2020;37(6):2865–2883.
- Augustin M, et al. Dermatol Ther (Heidelb) 2026. DOI:10.1007/s13555-026-01722-0.
- Kiltz U, et al. Poster POS0234. Ann Rheum Dis 2021;80:337–338.
- Kiltz U, et al. P2344. American College of Rheumatology (ACR) Convergence. 14–19 November 2024; Washington, DC, US.
- Augustin M, et al. Poster P62689. American Academy of Dermatology (AAD) Congress. 7–11 March 2025; Orlando, FL, US.
- Kiltz U, et al. Poster POS0574. European Alliance of Associations for Rheumatology (EULAR) Congress 2025. 11–14 June 2025; Barcelona, Spain.
- Kiltz U, et al. Abstract ABS0605. European Alliance of Associations for Rheumatology (EULAR) Congress 2025. 11–14 June 2025; Barcelona, Spain.
IE11650303 | May 2026
